{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:19:44Z","timestamp":1792268384042,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100010724","name":"Health Systems Research Institute","doi-asserted-by":"crossref","award":["59-053"],"award-info":[{"award-number":["59-053"]}],"id":[{"id":"10.13039\/501100010724","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Heart Association of Thailand","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-024-03007-9","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T19:01:52Z","timestamp":1720551712000},"page":"97-108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Clinical outcomes of patients with atrial fibrillation in relation to multimorbidity status changes over time and the impact of ABC pathway compliance: a nationwide cohort study"],"prefix":"10.1007","volume":"58","author":[{"given":"Rungroj","family":"Krittayaphong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjbordin","family":"Winijkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komsing","family":"Methavigul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ply","family":"Chichareon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"3007_CR1","doi-asserted-by":"publisher","first-page":"100157","DOI":"10.1016\/j.lanepe.2021.100157","volume":"7","author":"SC Chung","year":"2021","unstructured":"Chung SC, Sofat R, Acosta-Mena D et al (2021) Atrial fibrillation epidemiology, disparity and healthcare contacts: a population-wide study of 5.6 million individuals. Lancet Reg Health Eur 7:100157","journal-title":"Lancet Reg Health Eur"},{"key":"3007_CR2","doi-asserted-by":"publisher","first-page":"102181","DOI":"10.1016\/j.cpcardiol.2023.102181","volume":"49","author":"S Elsheikh","year":"2023","unstructured":"Elsheikh S, Hill A, Irving G et al (2023) Atrial fibrillation and stroke: state-of-the-art and future directions. Curr Probl Cardiol 49:102181","journal-title":"Curr Probl Cardiol"},{"key":"3007_CR3","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1093\/eurheartj\/ehad571","volume":"44","author":"J Wu","year":"2023","unstructured":"Wu J, Nadarajah R, Nakao YM et al (2023) Temporal trends of cause-specific mortality after diagnosis of atrial fibrillation. Eur Heart J 44:4422\u20134431","journal-title":"Eur Heart J"},{"key":"3007_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/ehjqcco\/qcaa093","volume":"8","author":"P Burdett","year":"2022","unstructured":"Burdett P, Lip GYH (2022) Atrial fibrillation in the Uk: Predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs. Eur Heart J Qual Care Clin Outcomes 8:187\u2013194","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"3007_CR5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1136\/heartjnl-2020-317299","volume":"107","author":"T Maeda","year":"2021","unstructured":"Maeda T, Nishi T, Funakoshi S et al (2021) Residual risks of ischaemic stroke and systemic embolism among atrial fibrillation patients with anticoagulation: large-scale real-world data (f-create project). Heart 107:217\u2013222","journal-title":"Heart"},{"key":"3007_CR6","doi-asserted-by":"crossref","unstructured":"Krittayaphong R, Chichareon P, Komoltri C et al (2023) Predicting heart failure in patients with atrial fibrillation: a report from the prospective cool-af registry. J Clin Med, 12","DOI":"10.3390\/jcm12041265"},{"key":"3007_CR7","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1177\/2047487317715769","volume":"24","author":"V Ruddox","year":"2017","unstructured":"Ruddox V, Sandven I, Munkhaugen J et al (2017) Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: a systematic review and meta-analysis. Eur J Prev Cardiol 24:1555\u20131566","journal-title":"Eur J Prev Cardiol"},{"key":"3007_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/ehjqcco\/qcy033","volume":"5","author":"Y An","year":"2019","unstructured":"An Y, Ogawa H, Yamashita Y et al (2019) Causes of death in Japanese patients with atrial fibrillation: the fushimi atrial fibrillation registry. Eur Heart J Qual care Clin Outcomes 5:35\u201342","journal-title":"Eur Heart J Qual care Clin Outcomes"},{"key":"3007_CR9","doi-asserted-by":"publisher","first-page":"e0282455","DOI":"10.1371\/journal.pone.0282455","volume":"18","author":"R Krittayaphong","year":"2023","unstructured":"Krittayaphong R, Boonyapiphat T, Aroonsiriwattana S et al (2023) Causes of death of patients with non-valvular atrial fibrillation in asians. PLoS ONE 18:e0282455","journal-title":"PLoS ONE"},{"key":"3007_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/ehjqcco\/qcaa070","volume":"8","author":"PV Rasmussen","year":"2022","unstructured":"Rasmussen PV, Pallisgaard JL, Hansen ML et al (2022) Treatment of older patients with atrial fibrillation by morbidity burden. Eur Heart J Qual care Clin Outcomes 8:23\u201330","journal-title":"Eur Heart J Qual care Clin Outcomes"},{"key":"3007_CR11","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1016\/j.mayocp.2019.06.012","volume":"94","author":"M Proietti","year":"2019","unstructured":"Proietti M, Marzona I, Vannini T et al (2019) Long-term relationship between atrial fibrillation, multimorbidity and oral anticoagulant drug use. Mayo Clin Proc 94:2427\u20132436","journal-title":"Mayo Clin Proc"},{"key":"3007_CR12","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","volume":"14","author":"GYH Lip","year":"2017","unstructured":"Lip GYH (2017) The abc pathway: an integrated approach to improve af management. Nat Reviews Cardiol 14:627\u2013628","journal-title":"Nat Reviews Cardiol"},{"key":"3007_CR13","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1055\/a-1515-9630","volume":"122","author":"GF Romiti","year":"2022","unstructured":"Romiti GF, Pastori D, Rivera-Caravaca JM et al (2022) Adherence to the \u2018atrial fibrillation better care\u2019 pathway in patients with atrial fibrillation: impact on clinical outcomes-a systematic review and meta-analysis of 285,000 patients. Thromb Haemost 122:406\u2013414","journal-title":"Thromb Haemost"},{"key":"3007_CR14","doi-asserted-by":"publisher","first-page":"e028463","DOI":"10.1161\/JAHA.122.028463","volume":"12","author":"R Krittayaphong","year":"2023","unstructured":"Krittayaphong R, Winijkul A, Methavigul K et al (2023) Impact of achieving blood pressure targets and high time in therapeutic range on clinical outcomes in patients with atrial fibrillation adherent to the atrial fibrillation better care pathway: a report from the cool-af registry. J Am Heart Association 12:e028463","journal-title":"J Am Heart Association"},{"key":"3007_CR15","doi-asserted-by":"crossref","unstructured":"Camacho EM, Lip GYH (2023) Estimating the impact of implementing an integrated care management approach with atrial fibrillation better care (abc) pathway for patients with atrial fibrillation in England from 2020\u20132040. European heart journal Quality of care & clinical outcomes","DOI":"10.1093\/ehjqcco\/qcad055"},{"key":"3007_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1055\/s-0041-1739411","volume":"122","author":"TF Chao","year":"2022","unstructured":"Chao TF, Joung B, Takahashi Y et al (2022) 2021 focused update consensus guidelines of the asia pacific heart rhythm society on stroke prevention in atrial fibrillation: executive summary. Thromb Haemost 122:20\u201347","journal-title":"Thromb Haemost"},{"key":"3007_CR17","first-page":"204887261880176","volume":"10","author":"YG Li","year":"2018","unstructured":"Li YG, Borgi M, Lip GY (2018) Atrial fibrillation occurring initially during acute medical illness: the heterogeneous nature of disease, outcomes and management strategies. Eur Heart J Acute Cardiovasc Care 10:2048872618801763","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"3007_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2020","unstructured":"Hindricks G, Potpara T, Dagres N et al (2020) 2020 esc guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association of cardio-thoracic surgery (eacts). Eur Heart J 42:373\u2013498","journal-title":"Eur Heart J"},{"key":"3007_CR19","doi-asserted-by":"crossref","unstructured":"Schulman S, Kearon C et al (2005) Subcommittee on Control of Anticoagulation of the S,. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of thrombosis and haemostasis: JTH, 3: 692\u2013694","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"3007_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0038-1651587","volume":"69","author":"FR Rosendaal","year":"1993","unstructured":"Rosendaal FR, Cannegieter SC, van der Meer FJ et al (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69:236\u2013239","journal-title":"Thromb Haemost"},{"key":"3007_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2217\/fca-2020-0014","volume":"17","author":"JP Bassand","year":"2021","unstructured":"Bassand JP, Apenteng PN, Atar D et al (2021) Garfield-af: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke. Future Cardiol 17:19\u201338","journal-title":"Future Cardiol"},{"key":"3007_CR22","doi-asserted-by":"crossref","unstructured":"Chan YH, See LC, Tu HT et al (2018) Efficacy and safety of apixaban, dabigatran, rivaroxaban, and warfarin in asians with nonvalvular atrial fibrillation. J Am Heart Association, 7","DOI":"10.1161\/JAHA.117.008150"},{"key":"3007_CR23","doi-asserted-by":"crossref","unstructured":"Romiti GF, Guo Y, Corica B et al (2023) Mobile health-technology-integrated care for atrial fibrillation: a win ratio analysis from the mafa-ii randomized clinical trial. Thromb Haemost","DOI":"10.1055\/s-0043-1769612"},{"key":"3007_CR24","doi-asserted-by":"crossref","unstructured":"Treewaree S, Lip GYH, Krittayaphong R (2023) Non-vitamin k antagonist oral anticoagulant, warfarin, and abc pathway adherence on hierarchical outcomes: Win ratio analysis of the cool-af registry. Thromb Haemost","DOI":"10.1055\/s-0043-1772773"},{"key":"3007_CR25","unstructured":"Writing Committee M, Joglar JA, Chung MK et al (2023) 2023 acc\/aha\/accp\/hrs guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines. J Am Coll Cardiol"},{"key":"3007_CR26","doi-asserted-by":"publisher","first-page":"101752","DOI":"10.1016\/j.cpcardiol.2023.101752","volume":"48","author":"M Proietti","year":"2023","unstructured":"Proietti M, Romiti GF, Corica B et al (2023) Features of clinical complexity in European patients with atrial fibrillation: a report from a European observational prospective af registry. Curr Probl Cardiol 48:101752","journal-title":"Curr Probl Cardiol"},{"key":"3007_CR27","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2169\/internalmedicine.6077-20","volume":"60","author":"H Hori","year":"2021","unstructured":"Hori H, Fukuchi T, Sugawara H (2021) Anticoagulant therapy for frail patients with atrial fibrillation. Intern Med 60:495\u2013506","journal-title":"Intern Med"},{"key":"3007_CR28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/ageing\/afy180","volume":"48","author":"C Wilkinson","year":"2019","unstructured":"Wilkinson C, Todd O, Clegg A et al (2019) Management of atrial fibrillation for older people with frailty: a systematic review and meta-analysis. Age Ageing 48:196\u2013203","journal-title":"Age Ageing"},{"key":"3007_CR29","doi-asserted-by":"publisher","first-page":"101652","DOI":"10.1016\/j.arr.2022.101652","volume":"79","author":"M Proietti","year":"2022","unstructured":"Proietti M, Romiti GF, Raparelli V et al (2022) Frailty prevalence and impact on outcomes in patients with atrial fibrillation: a systematic review and meta-analysis of 1,187,000 patients. Ageing Res Rev 79:101652","journal-title":"Ageing Res Rev"},{"key":"3007_CR30","doi-asserted-by":"publisher","first-page":"215013192211299","DOI":"10.1177\/21501319221129935","volume":"13","author":"G Reig-Garcia","year":"2022","unstructured":"Reig-Garcia G, Camara-Liebana D, Jimenez-Quinones R et al (2022) Control of therapeutic levels of anticoagulation and associated factors: a prospective cohort study. J Prim Care Community Health 13:21501319221129935","journal-title":"J Prim Care Community Health"},{"key":"3007_CR31","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/PPA.S120962","volume":"11","author":"S Zhao","year":"2017","unstructured":"Zhao S, Zhao H, Wang X et al (2017) Factors influencing medication knowledge and beliefs on warfarin adherence among patients with atrial fibrillation in China. Patient Prefer Adherence 11:213\u2013220","journal-title":"Patient Prefer Adherence"},{"key":"3007_CR32","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1055\/s-0039-3401823","volume":"120","author":"AK Pandey","year":"2020","unstructured":"Pandey AK, Xu K, Zhang L et al (2020) Lower versus standard inr targets in atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Thromb Haemost 120:484\u2013494","journal-title":"Thromb Haemost"},{"key":"3007_CR33","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1055\/a-2021-8910","volume":"123","author":"JW Eikelboom","year":"2023","unstructured":"Eikelboom JW, Weitz JI (2023) Direct oral anticoagulants in the very elderly. Thromb Haemost 123:377\u2013379","journal-title":"Thromb Haemost"},{"key":"3007_CR34","doi-asserted-by":"publisher","first-page":"e0292586","DOI":"10.1371\/journal.pone.0292586","volume":"18","author":"EM Trinks-Roerdink","year":"2023","unstructured":"Trinks-Roerdink EM, Geersing GJ, van den Dries CJ et al (2023) Integrated care in patients with atrial fibrillation- a predictive heterogeneous treatment effect analysis of the all-in trial. PLoS ONE 18:e0292586","journal-title":"PLoS ONE"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-03007-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-024-03007-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-03007-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T18:24:49Z","timestamp":1737829489000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-024-03007-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["3007"],"URL":"https:\/\/doi.org\/10.1007\/s11239-024-03007-9","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"20 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GYHL: Consultant and speaker for BMS\/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Anthos. No fees are received personally. He is a National Institute for Health and Care Research (NIHR) Senior Investigator and co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union\u2019s Horizon 2020 research and innovation programme under grant agreement No 899871.Other authors hereby declare no personal or professional conflicts of interest relating to any aspect of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}